NeuroVasx cPAX Aneurysm Treatment System: first procedure in Spain performed

NeuroVasx, Inc., a medical device company that develops technologies for the treatment of hemorrhagic and ischemic stroke, announced today that the first procedure in Spain utilizing its cPAX Aneurysm Treatment System was performed in Madrid. cPAX received CE Mark earlier this year.

Dr. Alfredo Casasco, Interventional Neuroradiology, Department of Endovascular and Percutaneous Treatment, Clinica Nuestra Senora del Rosario, used 143cm of cPAX in combination with platinum coils to treat an unruptured aneurysm over 13mm in diameter.

"According to the AngioCalc aneurysm volume calculator, greater than 40% packing density was achieved with cPAX alone, which we see as a great result," said Kathryn Meintsma, Vice President of Marketing, NeuroVasx. "Studies have indicated that aneurysms packed greater than 24% have a lower incidence of recanalization."(1,2)

"We are very pleased with the outcome of the first procedure in Spain, which demonstrates the sophisticated filling capabilities of cPAX in large aneurysms," said Eric B. Timko, President and Chief Executive Officer, NeuroVasx. "cPAX was designed to simplify delivery, shorten procedure time and improve outcomes, and the product's polymer characteristics make it ideally suited to take on the shape of large aneurysms and attain maximized packing density. This case marks a significant milestone in our entry into the European market and we look forward to continuing to introduce cPAX throughout the EU."

Source:

NeuroVasx, Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Decoding the genetic roots of stroke and heart attack